The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines

Perdrizet, Johnna; Farkouh, Raymond; Horn, Emily; Hayford, Kyla; Sings, Heather L.; Wasserman, Matt

doi:10.1080/14760584.2022.2040989

Cited by 6 publications

(8 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, these costs can be important contributors to cost-effectiveness models. We agree with the authors of this letter that it is important to capture the full societal benefits of vaccination, which have been shown to be greater than the more limited direct [ 14 , 15 ]. Therefore, our annual economic burden results of $118 million for PCV15 and $214 million for PCV20 can be considered conservative.…”

supporting

confidence: 70%

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’

Rozenbaum

Perdrizet

et al. 2022

Infect Dis Ther

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 70%

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’

Rozenbaum

Perdrizet

et al. 2022

Infect Dis Ther

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Given the paucity of published data from vaccine trials to support or refute our findings, further investigation of biological plausibility is warranted, particularly as higher valency vaccines become available. [20] Our systematic review identified an almost complete absence of published contemporary (post PCVera) data on the prevalence and persistence of hearing loss in very young First Nations children. [21] In addition, data from the NT hearing outreach services show that only 11% of services (either audiology, Clinical Nurse Specialist, or ear, nose and throat (ENT) teleotology) were provided to children under age 3 years.…”

Section: Discussionmentioning

confidence: 99%

Hearing loss at 6-monthly assessments from age 12 to 36 months: secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

Leach,

Wilson,

Arrowsmith

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: In remote communities, Australian First Nations children with hearing loss are disproportionately at risk of poor school readiness and performance, compared to those with normal hearing. Our objective was to compare two pneumococcal conjugate vaccine (PCV) formulations and mixed schedules (the PREVIX trials) designed to broaden protection and reduce conductive hearing loss to age 36 months. Methods: In two sequential parallel, open-label, randomised controlled trials, eligible infants were first allocated 1:1:1 at age 28-38 days to standard or mixed PCV primary schedules, then at age 12 months to a booster dose (1:1) of PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine, +S). Here we report secondary hearing outcomes in the +P and +S groups at 6-monthly scheduled assessments from age 12 to 36 months. Findings: From March 2013 to September 2018, 461 hearing assessments were performed. Prevalence of mild- moderate hearing loss declined in both groups from ~75% at age 12 months to ~53% at 36 months. At primary endpoint age 18 months, prevalence of moderate (disabling) hearing loss was 21% and 41% in the +P and +S groups, respectively (difference -19% [95% confidence interval -38, -1], p=0.07) and prevalence of normal hearing was 36% and 16%, respectively (difference 19% [95%CI 2, 37], p=0.05). At subsequent timepoints prevalence of moderate hearing loss remained lower in the +P group at -3% [95% CI -23, 18] at age 24 months, -12% [95%CI -30, 6] at 30 months, and -9% [95%CI -23, 5] at 36 months. Interpretation: This study provides first evidence of the high prevalence and persistence of mild and moderate hearing loss throughout early childhood. A lower prevalence of moderate (disabling) hearing loss in the +P group may have substantial benefits for high-risk children and warrants further investigation.

show abstract

“…Introduction of the vaccine led to decreased rates of hospitalization and death for the Australian population [7]. It has also decreased rates of IPD by up to 93 % in vaccinated children <5 years old, but protection from OM remains poor in both adults and children and causes significant morbidity and mortality [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

A case report of disseminated Streptococcus pneumoniae infection complicated by infective endocarditis, septic arthritis and epidural abscess in an immunocompetent patient

Dean

Koirala

Samarasekara

2023

Access Microbiology

View full text Add to dashboard Cite

Streptococcus pneumoniae is a highly virulent, vaccine-preventable pathogen which can cause disease on a spectrum from benign to fatal. Apart from pneumonia, it commonly causes septicaemia and meningitis. This case report describes an unusual range of complications in a 53-year-old Caucasian female presenting to a regional hospital, without any risk known factors for severe disease (such as extremes of age, immunodeficiency or co-morbidities). Progressing from an episode of otitis media, her condition rapidly progressed to mastoid sinusitis, septic arthritis, infective endocarditis, epidural abscesses and multiple subcutaneous abscesses. Following quick identification of S. pneumoniae from a positive blood culture, the patient was treated with high-dose benzylpenicillin and ceftriaxone and aggressive source control by surgery, enabling a good clinical recovery.

show abstract

The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines

Cited by 6 publications

References 131 publications

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’

Hearing loss at 6-monthly assessments from age 12 to 36 months: secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

A case report of disseminated Streptococcus pneumoniae infection complicated by infective endocarditis, septic arthritis and epidural abscess in an immunocompetent patient

Contact Info

Product

Resources

About